77
Participants
Start Date
July 1, 2022
Primary Completion Date
November 28, 2024
Study Completion Date
November 28, 2024
ATH434 dose level 1
ATH434 taken BID
ATH434 dose level 2
ATH434 taken BID
Placebo
Placebo taken BID
Columbia University Irving Medical Center, New York
CHU de Marseille/Hôpital de la Timone, Marseille
Johns Hopkins University, Baltimore
CHU de Toulouse/Hôpital Pierre-Paul Riquet, Toulouse
CHU de Bordeaux/Groupe Hospitalier Pellegrin, Bordeaux
Vanderbilt University Medical Center, Nashville
Rush University Medical Center, Chicago
The Movement Disorder Clinic of Oklahoma, Tulsa
CHU/HU Pitié Salpêtrière, Paris
University of California San Diego, La Jolla
St Vincent's Hospital (Sydney), Darlinghurst
Westmead Hospital, Westmead
The Alfred Hospital, Melbourne
IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna
Policlinico di Milano, Milan
Azienda Ospedaliero-Universitaria Pisana, Pisa
AOU San Giovanni di Dio Ruggi d'Aragona, Salerno
New Zealand Brain Research Institute, Christchurch
Auckland City Hospital, Grafton
University College London, London
Newcastle University, Newcastle upon Tyne
Salford Royal Hospital, Salford
Queen Elizabeth University Hospital, Glasgow
Lead Sponsor
Alterity Therapeutics
INDUSTRY